ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO276

The Effect of Magnesium Supplementation on Albuminuria in Patient With Type 2 Diabetic Mellitus in Phramongkutklao Hospital: A Randomized Double-Blinded Controlled Trial

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Santhitisate, Sriladda, Phramongkutklao Hospital, Bangkok, Thailand
  • Varothai, Narittaya, Phramongkutklao Hospital, Bangkok, Thailand
Background

Hypomagnesemia is associated with the development of microvascular complications including albuminuria in type 2 diabetes mellitus patients. It can also worsen glycemic control by promoting insulin resistance. Although there are several studies showed benefits of magnesium in patients with type 2 diabetes mellitus, there is no recommendation in recent guidelines that dietary mineral supplementation can improve outcomes in patients who do not have underlying deficiencies. This study was aimed to compare the effect of magnesium supplementation on albuminuria in type 2 diabetes mellitus patients.

Methods

This randomized double-blinded controlled trial included 26 patients who have moderately or severely increased albuminuria and normomagnesemia. Subjects were randomly divided in two groups to receive either 200 mg magnesium oxide or placebo daily for 6 months. Urine albumin-to-creatinine ratio, fasting plasma glucose, HbA1C, lipid profiles, kidney function were recorded at baseline and after the intervention. Magnesium intake was also assessed by 3-day food record.

Results

Every patients in this study had inadequate magnesium intake (lower than 30% of recommended daily allowance). Mean urine albumin-to-creatinine ratio were 143.61 +/- 115.87 mg/g in magnesium group and 466.36 +/- 989.28 mg/g in placebo group (p-value 0.247). Mean serum magnesium were 1.88 +/- 0.16 mg/dL in magnesium group and 1.77 +/- 0.10 mg/dL in placebo group (p-value 0.052). After 6-month treatment, there was no significant difference in degree of albuminuria between two groups (-47.48 +/- 89.05 vs 127.05 +/- 859.45, p-value 0.511). Fasting plasma glucose, HbA1C, lipid profiles and kidney function were also no significant differences except serum cholesterol level. Serum cholesterol were increased in both groups but significantly higher in placebo group (5.07 +/- 26.43 vs 24.25 +/- 18.68, p-value 0.049).

Conclusion

Magnesium supplementation showed no significant effect in albuminuria among patients with type 2 diabetes mellitus.